AZN - AstraZeneca PLC
| Previous Close | 38.35 |
| Open | 38.47 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 38.07 - 38.59 |
| 52 Week Range | 32.69 - 41.78 |
| Volume | 2,882,080 |
| Avg. Volume | 4,558,249 |
| Market Cap | 96.705B |
| Beta (3Y Monthly) | 0.66 |
| PE Ratio (TTM) | 40.03 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.58%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | N/A |
- The Wall Street Journal•6 hours ago
[$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time
China has for the first time approved a treatment from a global drugmaker before any other country, illustrating its recent push to bring in cutting-edge medicines—as well as Western companies’ growing interest in the market. The country’s medicines regulator on Tuesday approved roxadustat, a new anemia drug from AstraZeneca PLC and Fibrogen Inc., well ahead of any other nation. China approved 30 innovative drugs from foreign developers in the first nine months of this year—some taking just weeks—and, according to consulting firm McKinsey & Co., is on track to at least match last year’s 40 approvals, which marked the most by the regulator in any single year for at least a decade.
- American City Business Journals•9 hours ago
Why a kidney disease drug approval in China is just the start for this S.F. company
After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.
- Zacks•17 hours ago
BMY vs. AZN: Which Stock Should Value Investors Buy Now?
BMY vs. AZN: Which Stock Is the Better Value Option?
- Reuters•20 hours ago
China first to approve AstraZeneca, FibroGen anaemia drug
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.
- Reuters•20 hours ago
China first to approve AstraZeneca, FibroGen anaemia drug
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.
- Zacks•yesterday
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Market Realist•2 days agoHow Is AstraZeneca Faring in Chinese Markets?
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis. China accounted for around 56% of the company’s total emerging markets sales and 19% of the total revenues earned by the company in the first nine months of 2018.
Market Realist•2 days agoThese New Products Are Driving AstraZeneca’s Growth in Fiscal 2018
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis. In the first nine months of 2018, AstraZeneca reported new cardiovascular, renal, and metabolism (or CVRM) product sales worth $2.90 billion, which is a YoY rise of 14% on an actual basis and 12% on a CER basis.
Market Realist•5 days agoWhat Are AstraZeneca’s Growth Drivers in Fiscal 2018?
How Is AstraZeneca Positioned in December? In the third quarter, AstraZeneca (AZN) managed to surpass consensus adjusted EPS estimates by $0.27. In the third quarter, AstraZeneca reported operating profit of $851 million, which is a YoY decline of 26% on an actual basis and 21% on a constant exchange rate (or CER) basis.
- Zacks•5 days ago
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Market Realist•5 days agoA Look at AstraZeneca’s Expense Projections for Fiscal 2018
How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported selling, general, and administrative (or SG&A) expenses of $7.43 billion, which is a YoY rise of 4% on an actual basis and 1% on a constant exchange rate (or CER) basis. The company reported core SG&A expenses of $6.21 billion in the first nine months of 2018, which is a YoY rise of 10% on an actual basis and 7% on a CER basis.
Market Realist•5 days agoWhat Are AstraZeneca’s Margin Projections for Fiscal 2018
How Is AstraZeneca Positioned in December? AstraZeneca (AZN) reported a gross margin of 79.8% in the first nine months of 2018, which is a decline of 200 basis points on a YoY basis. Wall Street analysts expect AstraZeneca to report a gross margin of 80.40% in fiscal 2018, which would be a YoY decline of 39 basis points.
Market Realist•5 days agoWhat to Expect from AstraZeneca’s Earnings in Fiscal 2018
How Is AstraZeneca Positioned in December? In its third-quarter earnings conference call, AstraZeneca (AZN) reiterated its core EPS guidance of $3.30–$3.50 at a constant exchange rate (or CER). In the third quarter, AstraZeneca posted core EPS of $0.71, which is a YoY decline of 37% on an actual basis and 33% on a CER basis.
Market Realist•6 days agoWhat Analysts Recommend for AstraZeneca in December
How Is AstraZeneca Positioned in December? On December 11, AstraZeneca (AZN) closed at $38.66, which is 0.65% higher than its previous closing price. AstraZeneca has risen 3.40% from $38.51 on November 1 to $39.82 on November 30.
Market Realist•6 days agoWhat’s the Market Opportunity for Zejula?
How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of AZN.L earnings conference call or presentation 26-Jul-18 11:30am GMT
Q2 2018 AstraZeneca PLC Earnings Call
Market Realist•7 days agoA Look at Expansion Plans for Zejula
On October 22, 2018, AstraZeneca (AZN) issued a press release announcing positive results from Phase 3 trial SOLO-1, which evaluated PARP inhibitor Lynparza as a first-line maintenance therapy in ovarian cancer patients with germline BRCA (or gBRCA) mutations. The robust data from this trial in terms of improvement in progression-free survival has made a strong case for the advancement of other PARP inhibitors in the maintenance setting for first-line ovarian cancer patients.
- Insider Monkey•7 days ago
Here is What Hedge Funds Think About AstraZeneca plc (AZN)
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]
- InvestorPlace•8 days ago
Moderna Stock Ushers In the Next Wave of Biotech
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
- Benzinga•8 days ago
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...
- Motley Fool•8 days ago
Can Moderna Stock Recover From Its Initial Setback?
The largest biotech unicorn of its time is trying to get back up after stumbling out of the gate.
- Insider Monkey•10 days ago
Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Bloomberg•11 days agoNew Biotech IPO Dropped a Unicorn-Sized Value on Its First Day
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
